Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer
Background/Aims: Cetuximab is a chimeric IgG1 monoclonal antibody which targets the extracellular domain of epidermal growth factor receptor.This antibody is widely used for colorectal cancer (CRC) treatment but its influence on the immune ACTIVE B COMPLEX system is incompletely understood.Methods: The immune influence of cetuximab therapy in CRC p